ARS Pharmaceuticals Inc. (SPRY), which launched neffy 2mg in the U.S. last month, is expected to launch the product in the EU this quarter.
neffy 2 mg is a nasal spray used to treat life-threatening, allergic emergencies including anaphylaxis, in adults and children who weigh 66 lbs or more (30 kg or more), who are at risk for or have a history of serious allergic emergencies and it was approved in the U.S. and EU in August of this year. The trade name for neffy in the EU is EURneffy. It is the first and only needle-free treatment for type I allergic reactions, including anaphylaxis.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.